

Applications of Nanorobots in Medical Techniques

Pravin Hadwale^{1*}, Ashwini Gaikwad², Rushikesh Gade¹, Sandesh Panmand¹, Akash Tattu¹

Department of Pharmacy, Samarth College of Pharmacy, Belhe, Pune, Maharashtra, India¹

²Assistant Professor, Samarth College of Pharmacy, Belhe, Pune, Maharashtra, India.

Corresponding Author: Pravin Hadwale*

pravinhadwale12@gmail.com

Abstract: *Nanorobots, with their minuscule size ranging from 1 to 100 nanometers, have emerged as a revolutionary force in the realm of medical technology. This abstract explores the diverse applications of nanorobots, showcasing their potential to reshape diagnostics, drug delivery, surgery, and patient monitoring. Equipped with advanced sensors and imaging capabilities, nanorobots hold the promise of early disease detection by navigating the bloodstream and monitoring biomarkers. Their role in drug delivery involves precise transport of therapeutic agents to targeted cells, minimizing side effects and enhancing treatment efficacy. In the surgical domain, nanorobots enable minimally invasive procedures, performing intricate tasks at the cellular or molecular level. Continuous monitoring and intervention capabilities make nanorobots invaluable for proactive healthcare management. Moreover, in targeted cancer therapy, these microscopic marvels can deliver therapeutic payloads directly to cancer cells, offering a promising avenue for minimizing collateral damage. Despite these transformative potentials, challenges related to biocompatibility and safety necessitate further exploration. The applications of nanorobots in medical techniques represent a paradigm shift, holding the potential to redefine patient care and treatment strategies.*

Keywords: Nanorobots, Nanotechnology, Cancer Treatment, Surgery, Medicine, Healthcare, Gene Therapy, Component, Nano-surgery, Disease Management

REFERENCES

- [1]. Robert Freitas Jr A. The Ideal Gene Delivery Vector: Chromalloytes, Cell Repair Nanorobots for Chromosome Replacement Therapy, *Journal of Evolution and Technology*, 16(1), 2007, 1-97.
- [2]. Pingoud A, Jeltsch A. Structure and function of type II restriction endonucleases, *Nucleic Acids Res*, 29(18), 2001, 3705-3727.
- [3]. Kraulis P J, Raine A R, Gadhavi P L, Laue E D. Structure of the DNA-binding domain of zinc GAL4, *Nature*, 356(6368), 1992, 448-450.
- [4]. Von Hippel P H, Berg O G. Facilitated target location in biological systems, *J. Biol. Chem*, 264(2), 1989, 675-678.
- [5]. Robinson C R, Sligar S G. Changes in solvation during DNA binding and cleavage are critical to altered specificity of the EcoRI endonuclease, *Proc. Natl Acad. Sci. (USA)*, 95(5), 1998, 2186-2191.
- [6]. Sidorova N Y, Rau D C. Differences in water release for the binding of EcoRI to specific and nonspecific DNA sequences, *Proc. Natl Acad. Sci. (USA)*, 93(22), 1996, 12272-12277.
- [7]. Jeltsch A, Alves J, Wolfes H, Maass G, Pingoud A. Pausing of the restriction endonuclease EcoRI during linear diffusion on DNA, *Biochemistry*, 33(34), 1999, 10215-10219.
- [8]. Grundt K, Skjeldal L, Anthonsen H W, Skauge T, Huitfeldt H S, Ostvold A C. A putative DNA-binding domain in the NUCKS protein, *Arch. Biochem. Biophys*, 407(2), 2002, 168-175.
- [9]. Shioi S, Ose T, Maenaka K, Shiroishi M, Abe Y, Kohda D, Katayama T, Ueda T. Crystal structure of a biologically functional form of PriB from *Escherichia coli* reveals a potential single-stranded DNA-binding site, *Biochem. Biophys. Res. Commun*, 326(4), 2005, 766-776.
- [10]. Trumbore M W, Wang R H, Enkemann S A, Berger S L. Prothymosin alpha in vivo contains phosphorylated glutamic acid residues, *J. Biol. Chem*, 272(42), 1997, 26394-26404.

- [11]. Dobbstein M, Strano S, Roth J, Blandino G. p73-induced apoptosis: a question of compartments and cooperation, *Biochem. Biophys. Res. Commun*, 331(3), 2005, 688- 693.
- [12]. Chapter 24. Mechanics of Biological Nanotechnology, in Bharat Bhushan, ed., *Springer Handbook of Nanotechnology*, Springer-Verlag, Berlin, 2004, 755-760.
- [13]. Jinesh K B, Frenken J W M. Capillary condensation in atomic scale friction: how water acts like a glue, *Phys. Rev. Lett*, 96(16), 2006, 166103.
- [14]. Egger M, Heyn S P, Gaub H E. Synthetic lipid-anchored receptors based on the binding site of a monoclonal antibody, *Biochim. Biophys. Acta*, 1104(1), 1992, 45- 54.
- [15]. Marius P, Alvis S J, East J M, Lee A G. The interfacial lipid binding site on the potassium channel KcsA is specific for anionic phospholipids, *Biophys. J*, 89(6), 2005, 4081-4089.
- [16]. Hornig C, Albert D, Fischer L, Hornig M, Radmark O, Steinhilber D, Werz O. 1 Oleoyl-2-acetyl-glycerol stimulates 5- lipoxygenase activity via a putative (phospho) lipid binding site within the Nterminal C2-like domain, *J. Biol. Chem*, 280(29), 2005, 26913-26921.
- [17]. Van Loon D, Berkhout T A, Demel R A, Wirtz K W. The lipid binding site of the phosphatidylcholine transfer protein from bovine liver, *Chem. Phys. Lipids*, 38(1-2), 1985, 29-39.
- [18]. Lerche M H, Kragelund B B, Bech L M, Poulsen F M. Barley lipid-transfer protein complexed with palmitoyl CoA: the structure reveals a hydrophobic binding site that can expand to fit both large and small lipid-like ligands, *Structure*, 5(2), 1997, 291-306.
- [19]. Springer T A, Wang J H. The threedimensional structure of integrins and their ligands, and conformational regulation of cell adhesion, *Adv. Protein Chem*, 68, 2004, 29-63.
- [20]. Faury G. Role of the elastin-laminin receptor in the cardiovascular system, *Pathol. Biol. (Paris)*, 46(7), 1998, 517-526.
- [21]. De Souza S J, Brentani R. Collagen binding site in collagenase can be determined using the concept of sense-antisense peptide interactions, *J. Biol. Chem*, 267(19), 1992, 13763-13767.
- [22]. Steffensen B, Wallon U M, Overall C M. Extracellular matrix binding properties of recombinant fibronectin type II-like modules of human 72-kDa gelatinase/type IV collagenase. High affinity binding to native type I collagen but not native type IV collagen, *J. Biol. Chem*, 270(19), 1995, 11555-11566.
- [23]. Sumper M, Hallmann A. Biochemistry of the extracellular matrix of Volvox, *Int. Rev. Cytol*, 180, 1998, 51-85.
- [24]. Freitas Jr R A. Exploratory design in medical nanotechnology: A mechanical artificial red cell, *Artificial Cells, Blood Substitutes, and Immobil. Biotech*, 26(4), 1998, 411-430.
- [25]. Prausnitz M R. Microneedles for transdermal drug delivery, *Adv. Drug Delivery Rev*, 56(5), 2004, 581-587.
- [26]. Christoforidis J B, Warden S M, Demattia M, D'Amico D J. In vivo redirection of retinal blood flow into borosilicate microcannulas in rabbits, *Graefes Arch. Clin. Exp. Ophthalmol*, 244(8), 2006, 1022-1025.
- [27]. Olsen T W, Feng X, Wabner K, Conston S R, Sierra D H, Folden D V, Smith M E, Cameron J D. Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment, *Am. J. Ophthalmol*, 142(5), 2006, 777-787.
- [28]. Li J, Li X, Luo T, Wang R, Liu C, Chen S, Li D, Yue J, Cheng Sh and Sun D: Development of a magnetic microrobot for carrying and delivering targeted cells. *Science Robotics* 2018; 3: 8829.
- [29]. Mehra P and Nabhi K: A Nanorobotics the changing face of dentistry. *International Journal of Science and Research* 2016; 5(3): 192-97.
- [30]. Padovani GC, Feitosa VP, Sauro S, Tay FR, Duran G, Paula AJ and Duran N: Advances in dental materials through nanotechnology facts, perspectives and toxicological aspects. *Trends in Biotechnology* 2015; 33: 621-36.
- [31]. Padovani GC, Feitosa VP, Sauro S, Tay FR, Duran G, Paula AJ and Duran N: Advances in dental materials through nanotechnology facts, perspectives and toxicological aspects. *Trends in Biotechnology* 2015; 33: 621-36.
- [32]. Alexander J H, Hafley G, Harrington R A, Peterson E D, Ferguson Jr T B, Lorenz T, Goyal A, Gibson M, Mack M J, Gennevois D, Califf R M. Efficacy and safety of edifoligide, an E2F transcription factor decoy,

- for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial, *Jama*, 294(19), 2005, 2446- 2454.
- [33]. Kulier A, Levin J, Moser R, RumpoldSeitlinger G, Tudor I C, Snyder-Ramos S A, Moehnle P, Mangano D T. Impact of preoperative anemia on outcome in patients undergoing coronary artery bypass graft surgery, *Circulation*, 116(5), 2007, 471-479.
- [34]. Birkmeyer N J, Charlesworth D C, Hernandez F, Leavitt B J, Marrin C A, Morton J R, Olmstead E M, O'Connor G T. Obesity and risk of adverse outcomes associated with coronary artery bypass surgery, *Circulation*, 97(17), 1998, 1689- 1694.
- [35]. Lukeman Hakkim S, Ranjitha A. Replacement of Heart Bypass Surgery Using Nanorobots: A Review, *International Journal of Novel Research in Engineering and Science*, 2(2), 2016, 7-12.
- [36]. Sharma MK and Gupta R: Nanorobotics the future of medicines. *Research in Pharmacy and Health Sciences* 2016; 2: 51-56.
- [37]. Bi C, Guix M, Johnson B, Jing W and Cappelleri D: Design of microscale magnetic tumbling robots for locomotion in multiple environments and complex terrains. *Micromachines* 2018; 9: 68
- [38]. Mehra P and Nabhi K: A nanorobotics the changing face of dentistry. *The International Journal of Science and Research* 2016; 5(3): 192-97.
- [39]. Cale T S, Lu J Q, Gutmann R J. Threedimensional integration in microelectronics: Motivation, processing, and thermomechanical modelling, *Chemical Engineering Communications*, 195(8), 2008, 847-88.
- [40]. Robert A F J. Current Status of Nanomedicine and Medical Nanorobotics, *Journal of Computational and Theoretical Nanoscience*, 2(1), 2005, 1-25.
- [41]. Kharwade M, Nijhawan M and Modani S. Nanorobots: A Future Medical Device in Diagnosis and Treatment, *Research Journal of Pharmaceutical, Biological and Chemical Sciences*, 4(2), 2013, 1299-1307